Would you offer adjuvant immune checkpoint therapy for a patient with resected mucosal melanoma with a tumor thickness >4.0 mm with negative LN involvement?

Although adjuvant therapy is an option for patients with thick cutaneous melanomas, based on the results of the KEYNOTE-716 clinical trial (as well as CheckMate76K clinical trials), these trials limited accruals to cutaneous melanoma patients only. Thus, the efficacy of adjuvant immune checkpoint therapy is not well established in mucosal melanoma. Even in trials of adjuvant checkpoint therapy in stage III melanoma, only CheckMate 238 had a few patients (29) with mucosal melanoma, but KEYNOTE-05...